The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option. In addition, treatment choices can change over time as more evidence becomes available.Use of these documents is the responsibility of the prescribing clinician and is subject to the HSE.ie terms of use.
Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie.
For information on open clinical trials please refer to the Cancer Trials Ireland website here and also to basket trials here.
Neuroendocrine Chemotherapy Regimens
| Regimen Name |
Indication |
|
Everolimus Monotherapy
Regimen
|
00320b
Treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.
00320c
The treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal origin in adults with progressive disease
|
|
Lutetium (177Lu) oxodotreotide (Lutathera®) Therapy
Regimen
|
00642a
Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive- gastroenteropancreatic neuroendocrine tumours (GEP- NETs) in adults.
|
|
SUNItinib 37.5mg Therapy
Regimen
|
00327a
Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults
|
